Case report details psoriasis as an immune-related adverse event caused by camrelizumab in a cancer patient, indicating crucial implications for treatment.
Immune checkpoint inhibitors (ICIs) are an emerging treatment strategy for cancer, working by activating T cells to suppress tumor growth. However, they can cause immune-related adverse events (irAEs), including psoriasis. We report a case of a patient with esophageal cancer who developed psoriasis 6 weeks after starting camrelizumab. The condition improved following the discontinuation of camrelizumab and treatment with a topical glucocorticoid and a vitamin D3 derivative ointment. At 6-month follow-up, the patient showed no recurrence of psoriatic lesions or tumor progression.
No takes yet. Share an insight, caveat, or question.
Duan et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: